Archives of Medical Research
Volume 37, Issue 6 , Pages 689-695 , August 2006

Celecoxib Inhibits Cellular Growth, Decreases Ki-67 Expression and Modifies Apoptosis in Ovarian Cancer Cell Lines

  • Víctor Vital-Reyes

      Affiliations

    • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
    • Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Cristina Rodríguez-Burford

      Affiliations

    • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • David C. Chhieng

      Affiliations

    • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Denise K. Oelschlager

      Affiliations

    • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Alejandro Reyes-Fuentes

      Affiliations

    • Hospital de Ginecología y Obstetricia, Centro Medico Nacional “La Raza,” Instituto Mexicano del Seguro Social, México City, México
    • ,
  • Mack Barnes

      Affiliations

    • Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • William E. Grizzle

      Affiliations

    • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
    • Corresponding Author InformationAddress reprint requests to: William E. Grizzle, MD, PhD, Department of Pathology, University of Alabama at Birmingham, ZRB, Room 408, 703 South 19th St., Birmingham AL 35294-007

Received 20 June 2005 ,Accepted 20 November 2005.

References 

  1. Ovarian Cancer. In the Early Detection Research Network. Translational Research to Identify Early Cancer and Cancer Risk. National Cancer Institute. NIH-Publication No. 02–5216. Second Report, October 2002. pp. 21–23.
  2. Cannistra SA. Cancer of the ovary. NEJM. 2004;351:2519–2529
  3. Barnes MN, Grizzle WE, Grubbs CJ, Partridge EE. Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin. 2002;52:216–225
  4. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003;4:431–436
  5. Thun MJ, Heneley JS, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–266
  6. Kiefer W, Dannhardt G. Novel insights and therapeutical applications in the field of inhibitors of COX-2. Curr Med Chem. 2004;11:3147–3161
  7. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, DeMarzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215:1–20
  8. Akhmeddkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prevent Med. 2002;33:682–687
  9. Moysich KB, Mettlin C, Piver M, Natarajan N, Menezes RJ, Swede W. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:903–906
  10. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 2002;8:202–209
  11. Rodriguez-Burford C, Oelschlager DK, Talley LI, Barnes MN, Partridge EE, Grizzle WE. The use of dimethylsulfoxide as a vehicle in cell culture experiments using ovarian carcinoma cell lines. Biotech Histochem. 2003;78:17–21
  12. Grizzle WE, Myers RB, Manne U, Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In:  Hanausek M,  Walazek Z editor. John Walker's Methods in Molecular Medicine–Tumor Marker Protocols. Totowa, NJ: Humana Press; 1998;p. 143–160
  13. Grizzle WE, Shibata D, Manne U, Myers RB, Frost AR. Molecular and histopathologic changes in the development of colorectal neoplasia. In:  Srivastava S, et al. editor. Molecular Pathology of Early Cancer. Amsterdam: IOS Press; 1999;p. 135–170
  14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond). 1970;227:680–685
  15. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst. 1994;86:1140–1145
  16. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrilamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979;76:4350–4354
  17. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein associated with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513–522
  18. Mohseni H, Zaslau S, McFadden D, Riggs DR, Jackson BJ, Kanszari S. COX-2 inhibition demonstrates potent antiproliferative effects on bladder cancer in vitro. J Surg Res. 2004;119:138–142
  19. Yang CY, Meng CL, Liao CL, Wong PYK. Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines. Prostaglandins Other Lipid Mediat. 2003;72:115–130
  20. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24:96–102
  21. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-inhibitor celecoxib. FASEB J. 2001;15:2742–2744
  22. Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, Weichert W, et al. Induction of G0/G1 arrest in ovarian cells by the anti-inflammatory drug NS-398, but not by COX-specific RNA interference. Oncogene. 2003;22:8653–8661
  23. Chen PY, Long QC. Effects on cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin. 2004;25:943–949
  24. Smith ER, Daly MR, Xiang-Xi X. A mechanism for COX-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidemiol Biomarkers Prev. 2004;23:144–145

PII: S0188-4409(06)00084-1

doi: 10.1016/j.arcmed.2005.11.014

Archives of Medical Research
Volume 37, Issue 6 , Pages 689-695 , August 2006

Article Tools

* Image Usage & Resolution